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ABSTRACT 
A double blind study was undertaken to compare the efficacy between centbutindole and 
haloperidol. A total of 44 patients suffering from schizophrenia diagnosed in accordance to ICD-10 
criteria were included. They were randomly assigned into two groups receiving centbutindole (4.5 
mg) or haloperidol (15 mg) in two divided doses per day for six weeks. Each patient was evaluated 
on Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression Scale (CGI-S) and 
UKU side effect scale every week. Five patients (1 patient in centbutindole group, 4 patients in 
haloperidol group) dropped out due to various reasons. A total of 39 patients (21 patients in 
centbutindole group and 18 patients in haloperidol group) completed the study. The results revealed 
an early onset of therapeutic effect with centbutindole for both positive and negative symptoms. 
However, the efficacy was comparable between centibutindole and haloperidol from 3rd week 
onwards. 
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Centbutindole is a new antipsychotic 
2-[gama - (P-fluorobenzoyl) propyl] -1,2,3,4,5,6,7, 
12,12a -octahydropyrazino (2', 1':6.1) pyrido (3,4-
b) indole related to butyrophenone group (Saxena 
et at., 1973). Preclinical^ it has been found to have 
blocked amphetamine induced hyperactivity/ 
stereotypy and conditioned avoidance responses 
(Dua et al.,1974). These effects have been found 
in doses (on miligram basis) lower than those 
required for chlorpromazine and haloperidol. The 
drug is a dopamine antagonist but it also affects 
5 HT2 receptors (Gulati,1990). The l-isomer of 
centbutindole is more active than the d-isomer 
(Singh et al.,1977). Clinically the drug'has gone 
through Phase I, II and III clinical trials successfully 
and it has shown effective antipsychotic activity 
in schizophrenic patients (Doongaji et al.,1983). 
The pharmacokinetic study in normal volunteers 
has shown that peak serum levels of centbutindole 
were reached at 4 hours and the plasma half life 
was 12 hours (Paliwal et al.,1992). However it 
does not produce striatal dopaminergic 
supersensitivity and therefore seems to have 
lesser potential to induce tardive dyskinesia on 
prolonged administration (Gulati et al.,1988). This 
communication reports the comparative clinical 
evaluation of centbutindole and haloperidol in 
patients of schizophrenia. 
MATERIAL AND METHOD 
The design of study was a double blind 
parallel trial comparing centbutindole with 
haloperidol. The subjects were schizophrenic 
patients diagnosed according to ICD-10 criteria. 
Patients satisfying both the inclusion and exclusion 
criteria were admitted in the hospital. They were 
randomised according to a pre-determined schedule 
to receive either halopendol or centbutindole for a 
period of 6 weeks. Adult patients of schizophrenia, 
having no prior drug treatment for 4 weeks or drug 
naive before inclusion, willing to accept oral 
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medication, between the age of 18 to 50 years were 
included in the trial. Patients with hypersensitivity 
to drug treatment, pregnancy or lactation, co-existing 
severe organic diseases, malignancy, depression, 
drug abuse, mental subnormality and patients 
requiring parenteral drug or ECT were excluded from 
the trial. Each patient/guardian executed informed 
written consent before inclusion in the study. These 
patients were subjected to a thorough clinical 
examination, haematologicai (haemoglobin, total 
leucocyte count, differential leucocyte count, 
erythrocyte sedimentation rate) and biochemical 
(serum bilirubin, SGOT, SGPT, alkaline 
phosphatase, blood sugar and blood urea) 
investigations. Each patient was then randomized 
to receive either centbutindole or haloperidol. The 
drug was formulated in capsules identical in colour, 
shape and size. Each capsule contained 
centbutindole (1.5 mg) or haloperidol (5 mg) and 
the maximum dose was 4.5 mg and 15 mg for 
centbutindole and haloperidol respectively. The total 
duration of the study was six weeks. During this 
study each patient was evaluated on Positive and 
Negative Syndrome Scale (PANSS) by Kay et 
al.(1987), UKU Side Effect Rating Scale by 
Lingjaerde et al.(1987) and Clinical Global 
Impression Scale (CGI-S) every week. Initially each 
patient received one capsule twice a day for first 
two weeks. At 3rd week if the PANSS was 50% or 
more no escalation in dose was made, on the other 
hand if PANSS score was <50%, the dose of the 
drug was escalated from -1 BD/day to 1 TDS/day. 
Trihexiphenidyl was added at the time of appearance 
of extrapyramidal side effects. The Data was 
analysed using 'f test for pre and post drug. 
RESULT 
A total of 44 patients of schizophrenia 
were included in the study. They were randomly 
assigned to two groups namely centbutindole and 
haloperidol respectively containing 22 patients 
in each group. Five out of 44 patients dropped 
out during the study, its groupwise distribution 
being 4 (9%) out of 22 patients in haloperidol 
group and 1(2%) out of 22 patients in 
centbutindole group. So finally 39 patients 
completed the study. 21 patients in centbutindole 
group and 18 patients in haloperidol group. The 
dosage of centbutindole or haloperidol was 
escalated from 1 capsule B.D. to 1 capsule 
T.D.S. in third week as in none of the cases 
PANSS score decreased by 50% till that time. 
The sociodemographic & clinical variables 
of the sample are given in table 1. This shows that 
there was no significant difference between 
centbutindole and haloperidol groups with respect 
to age, sex, domicile, onset, duration and number 
of episodes. In both positive and negative 
syndrome with centbutindole onset of effect was 
observed in the first and the second week but in 
the haloperidol group no significant decrease was 
observed (Table 2 & 3). A steady decline in scores 
was observed from 3-6 weeks with both the drugs 
but no significant differences was found between 
the two drugs. All the 4 individual factors namely 
thought disorganisation, activation, anergy and 
paranoid showed significant decrease from their 
TABLE 1 
SOCIO-DEIWOGRAPHIC AND CLINICAL 
VARIABLES OF THE SAMPLE 
Variables 
Age 
Sex(M/F) 
M.Status(lwS/W) 
Onset 
Ins/Act. 
Episode 
1st/>1 
Duration 
<1/>1 year 
Family History 
of Schizophrenia 
Present/Absent 
Centbutindole 
(n=22) 
Mean =29.55 years 
SD=±8.44 
13(59%): 9(41%) 
14(64%): 8(36%) 
21(95%): 1(5%) 
21(95%): 1(5%) 
6(27%): 16(73%) 
3(14%): 19(86%) 
Haloperidol 
(n=22) 
Mean=30.05 yrs. 
SD=±9.46 
13(59%):9(41%) 
14(64%):7(32%) 
21(95%):1(5%) 
22(100%):0(0%) 
11(50%):11(50%) 
1(5%):21(95%) 
TABLE 2 
CHANGE IN BASELINE SCORE IN PANSS 
SCALE ON POSITIVE SYNDROME 
Weeks 
n 
0 22 
1 21 
2 21 
3 21 
4 21 
5 21 
6 21 
Centbutindole 
Mean±SD t value 
27.24±5.67 
25.24±5.90 2.39* 
22.26±5 49 4.33*** 
20.57±5.44 5.44*** 
16.48±5.56 9.19*** 
13.10±5.17 9.33*** 
11.29±5.25 9.46*** 
n 
22 
22 
22 
18 
18 
18 
18 
Haloperido 
Mean±SD 
22.82±7.85 
21.91±7.03 
20.09±6.00 
18.50±4.77 
15.72±4.97 
12.28±4.60 
11.83±4.30 
I 
t value 
0.76 
1.91 
4.33*** 
7.16*** 
9.71*** 
10.65*** 
*pO05, *** p<0.001 
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TABLE 3 
CHANGE IN BASELINE SCORE IN PANSS 
ON NEGATIVE SYNDROME 
Weeks 
0 
1 
2 
3 
4 
5 
6 
n 
22 
21 
21 
21 
21 
21 
21 
Centbutindoie 
Mean±SD (value 
19.56±10.07 
17.76±10.35 2.22* 
16.19±09.76 5.96" 
n 
22 
22 
*22 
15.38±09.73 4.93*** 18 
13.86±09.86 5.27***18 
12.86±09.04 5.72** 
12.38±08.77 5.95*
v 
*18 
*18 
Haloperidol 
Mean±SD 
21.68±10.28 
20.86±09.65 
19.82±09.96 
18.22±08.33 
16.17±08.99 
14.61±08.78 
14.17±08.25 
t value 
1.08 
1.80 
2.57* 
3.29** 
4.38*** 
3.98*** 
*p<0.05. "p<0.01, ***p<0.001 
baseline scores at different points of time in the 
study but nowhere did the drugs differ significantly. 
However, in general psychopathology subscale 
both the drugs showed the significant decrease 
from the first week. The side effect analysis 
revealed that on psychic subscale 8 patients of 
the haloperidol group complained of inner unrest 
while only 4 patients on centbutindole complained 
of inner unrest. In the neurological subscale 2 
patients each developed akathisia and dystonia in 
haloperidol group while no patient developed these 
side effects in centbutindole group. The individual 
side effect profile of both drugs has been shown in 
table 4. The trihexiphenidyl (6 mg/day) was added 
in three divided doses at the time of appearance 
of side effects and continued in these cases upto 
the end of study. 
In the CGI scale, out of the 18 patients in 
haloperidol group, at the beginning of trial 2 
patients were severly ill, 8 patients were markedly 
ill and 8 patients were moderately ill. At the end 
of trial, 2 patients were 'very much improved', 8 
patients were much improved' and 8 patients 
were 'minimally improved'. In the centbutindole 
group, out of the total 21 patients, at the beginning 
of trial 2 patients were severly ill, 15 patients were 
markedly ill and 4 patients were moderately ill. At 
the end of trial of 8 patients were 'very much 
improved', 8 patients 'much improved' and 5 
patients were 'minimally improved'. 
DISCUSSION 
Centbutindole is a new antipsychotic 
developed by Central Drug Research Institute, 
TABLE 4 
INDIVIDUAL ClOE EFFECT PROFILE OF 
BOTH DRUGS 
Side Effects 
Psychic 
* Concentration Difficulties 
* Asthenia/Fatigue 
* Sleepiness/Sedation 
* Tension/Inner Uprest 
Centbutindole 
(n=22) 
15 
10 
10 
04 
* Increased Duration of-Sleep 10 
* Decreased Duration of Sleep 03 
* Increased Dream Activity 
Neurologic 
* Dystonia 
* Rigidity 
* Tremor 
* Akathisia 
Autonomic 
* Increased Salivation 
* Constipation 
* Increased Tendency 
of Sweating 
* Palpitation/Tachycardia 
08 
00 
11 
18 
00 
18 
10 
04 
00 
Haloperidol 
(n=22) 
15 
08 
08 
08 
08 
02 
04 
02 
14 
16 
02 
18 
08 
08 
02 
Lucknow. In this study centbutindole was 
compared with haloperidol using double blind 
parallel design. Out of 44 patients included in the 
trial 5 patients dropped out -1 patient belonged to 
centbutindole group and 4 patients received 
haloperidol giving drop out rates of 2% and 9% 
respectively. A closer look at the reasons of drop 
out showed that in haloperidol group - 2 patients 
were withdrawn in the first two weeks and had to 
be given parenteral medication and 
electroconvulsive therapy. Thus the drop out in 
the two patients was due to inability of the drug to 
control the symptom in first two weeks. Remaining 
2 patients opted out due to development of 
dystonia with haloperidol. 
The intergroup comparison showed 
centbutindole to have an earlier onset of action 
as it showed significant decrease in PANSS 
scores in first week while haloperidol did not show 
a significant decrease in the scores from 
baseline. However there was no significant 
difference between two drugs from third week 
onwards. The decrease in positive and negative 
symptoms was also similar in two groups. 
However, our study showed that centbutindole 
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had better results than haloperido) on the basis 
of clinical global impression scale. 
Thus after evaluating the findings of the 
present study it can be stated that this study was 
a comprehensive one with a 6 week duration. 
The standard diagnostic criteria were adhered 
to while selecting the sample. Double blind 
design was consistently maintained. The new 
drug centbutindole shows an earlier onset of 
action of anti-psychotic activity than with 
haloperidol. However no difference was 
observed between the drugs third week onwards. 
There is a clear need for novel 
antipsychotic medications that will treat a broader 
spectrum of symptoms beyond the typical drugs 
and do so with less potential for troublesome 
side effects (Goff & Shader, 1995). Centbutindole 
is a new anti-psychotic with different 
pharmacological profile. This pharmacological 
profile is closer to the atypical antipsychotics 
recently coming into the market. Centbutindole 
has shown an earlier onset of therapeutic effects 
with lesser potential to induce tardive dyskinesia 
on prolonged administration. 
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